Slide 1: Creating Value by Building Nanobusiness from Nanoscience
Creating Value by Building Nanobusiness from Nanoscience Exhibit 99.1
Slide 2: Market Opportunity: The Next Industrial Revolution
Market Opportunity: The Next Industrial Revolution Complexes between double-stranded DNA and the archaeal chromatin protein Protein ~ 2 – 100 nm long MicroElectroMechanical (MEMS) device 10 – m wide Carbon Nanotube ~1.3 nm diameter Ant ~ 5mm Red blood cells ~1.-5 m Quantum Corral of 48 Iron Atoms ~1
Slide 3: Arrowhead Capitalizes on Market Imbalances
• Research • Patents Investment Capital and Acquisitions Arrowhead Arrowhead Capitalizes on Market Imbalances Search for monetization Entrepreneurs Search for yield
Slide 4: Arrowhead Drop-in Solutions
Arrowhead Drop-in Solutions Initial management team Scientific thought leaders Finance Business Development Partnerships Acquisition Capital Raising We are not a hotel Clinical Trials Design Studies Preclinical Trials Design Studies Regulatory IP Protection Two Strategies: Build Companies de Novo an
Slide 5: Execution: Arrowhead Subsidiaries
Execution: Arrowhead Subsidiaries
Slide 6: Improving Drug Performance Through Effective Delivery
Improving Drug Performance Through Effective Delivery Phase I clinical trials underway using Cyclosert™ + off-patent compound, Camptothecin, and Phase II planned for later in 2008 O OH O H OH OH O O OH OH O O OH OH O O OH O OH O O H OH OH O H OH O O O H O O H O O H O O H O OH O H OH OH O O OH OH O O
Slide 7: Enhancing The Delivery and Therapeutic Uses of RNAi
Enhancing The Delivery and Therapeutic Uses of RNAi RNA interference (RNAi) is a natural mechanism to selectively turn off genes Calando’s delivery molecule self- assembles with siRNA and a targeting agent siRNA is protected and directed to target tissue IND Submitted • First Targeted siRNA • First
Slide 8: Tego fullerenes antioxidant patent portfolio
ROS Neutralized ROS ROS Neutralized ROS We believe Tego has a dominant patent portfolio for making and derivatizing fullerenes Fullerenes are powerful antioxidants Leveraging IP position and academic Partnerships to address: Next generation MRI imaging and Treatment for macular degeneration
Slide 9: Engineered Nanomaterials For Solid State Lighting And Solar Cells
Engineered Nanomaterials For Solid State Lighting And Solar Cells Blue LED Market Exceeds $4B They offer higher efficiency and longer lifetimes than conventional light sources However, current production techniques limit manufacturing yield and device efficiencies needed for broader market
Slide 10: Aonex Solution
Expensive gallium nitride source wafer Proprietary process for transfer of thin layers Highly optimized, inexpensive support wafer + Optimized wafer for LED, solar cell production Simplify production process Decrease costs Aonex Solution
Slide 11: Unidym: Carbon for Electronics
Unidym, Ine. 1430 O'Brien Drive, Suite G Menlo Park, CA 94026 Tel: (650) 462-1835 | yoyw.uiridyn.com © Unidym Carbon for Electronics
Slide 12: Carbon Nanotubes Properties
Carbon Nanotubes Properties Carbon nanotube (CNT) CNT film Electrical Mechanical Thermal Processing Cost 1000x more current capacity than copper Faster transistors than silicon 20x stronger than steel Comparable to diamond Compatible with inexpensive coating processes Comparable to current materials
Slide 13: CNTs Across Industries
CNTs Across Industries Electronics Materials Medicine Energy
Slide 14: Roll-up CNT Technologies & Capabilities
Roll-up CNT Technologies & Capabilities Nanopolaris Incorporated Initial University IP Roll Up Complete Acquisition of Unidym’s Product Line Complete Merger with CNI May 2005 December 2005 June 2006 April 2007 Created the dominant player in CNT production and applications
Slide 15: Build a Platform by Building a Product
Build a Platform by Building a Product • Leverage materials business for early revenue and development cycle • Strong growth in flat panel displays, interactive touch film devices and printable/flexible electronics • CNTs provide a unique fit of solutions, cost and performance benefits in all of the
Slide 16: Aonex & Tego 2008 Targets
Aonex & Tego 2008 Targets Aonex Sale: August Tego AMD lead compound selection: May Lead MRI contrast agent selection: July
Slide 17: Nanotope: The Next Regeneration
Nanotope The Next Regeneration
Slide 18: Central Issue for Therapeutics: Biological Barriers
Central Issue for Therapeutics: Biological Barriers • Endothelial and Epithelial Barriers • Reticulo-Endothelial System (RES) • Enzymatic Degradation • Hemo-Rheology • Tumor-Associated Osmotic & Interstitial Fluid Pressures • Cell, Endosomal Membrane • Nuclear Membrane • Ionic & Molecular Pumps Refe
Slide 19: Leonardo Biosystems
Leonardo Biosystems • Focus: Cancer Therapy • Multi-Stage Vectors • Strong IP Position
Slide 20: Strategy and Development
200 nm 1 µm 1 µm 20 nm 20 nm 20 nm Strategy and Development • Focus: Breast and Ovarian Cancer • MSV as platforms for Arrowhead’s Nanotechs Back Side Front Side Cross Section Nucleation Layer Pores Cross Section Competitive Advantages • Nanoporous Silicon as Platform Material – Fully Biodegradable,
Slide 21: Opportunity: Transition from replacement to enabling regeneration
Opportunity: Transition from replacement to enabling regeneration Nanotope’s Nanofibers: Unique Capabilities Self Assembly • Liquid to solid • Replace surgery with injection Mechanical Support • Guide scaffolding Bioactivity Biodegradable • Targeted signals • Sequestered signals
Slide 22: Arrowhead Research
Arrowhead Research
Slide 23: Arrowhead Research
Arrowhead Research
Slide 24: Healed: Nanotope Compound vs Non-healed Control
Healed: Nanotope Compound Non-healed: Control Wounds treated with Nanotope Compound Versus Control (12 days)